Corvus Pharmaceuticals (CRVS) Invested Capital (2022 - 2025)
Corvus Pharmaceuticals (CRVS) has 4 years of Invested Capital data on record, last reported at $71.8 million in Q3 2025.
- For Q3 2025, Invested Capital rose 478.35% year-over-year to $71.8 million; the TTM value through Sep 2025 reached $71.8 million, up 478.35%, while the annual FY2024 figure was $32.6 million, 15.81% down from the prior year.
- Invested Capital reached $71.8 million in Q3 2025 per CRVS's latest filing, down from $80.2 million in the prior quarter.
- Across five years, Invested Capital topped out at $89.7 million in Q1 2022 and bottomed at $12.4 million in Q3 2024.
- Average Invested Capital over 4 years is $53.5 million, with a median of $49.5 million recorded in 2023.
- Peak YoY movement for Invested Capital: tumbled 71.98% in 2024, then skyrocketed 478.35% in 2025.
- A 4-year view of Invested Capital shows it stood at $56.1 million in 2022, then plummeted by 31.06% to $38.7 million in 2023, then fell by 15.81% to $32.6 million in 2024, then surged by 120.36% to $71.8 million in 2025.
- Per Business Quant database, its latest 3 readings for Invested Capital were $71.8 million in Q3 2025, $80.2 million in Q2 2025, and $49.3 million in Q1 2025.